Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer

Trastuzumab emtansine (T-DM1), an antibody-drug conjugate consisted of the HER2-targeted monoclonal antibody trastuzumab and the tubulin inhibitor emtansine, has shown potent therapeutic value in HER2-positive breast cancer (BC). However, a clinical trial indicated that T-DM1 exerts a limited effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jinghui, Fan, Jiajun, Zeng, Xian, Nie, Mingming, Chen, Wei, Wang, Yichen, Luan, Jingyun, Zhu, Zeguo, Chang, Xusheng, Ju, Dianwen, Feng, Li, Yin, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969610/
https://www.ncbi.nlm.nih.gov/pubmed/33731670
http://dx.doi.org/10.1038/s41419-020-03349-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969610/
https://www.ncbi.nlm.nih.gov/pubmed/33731670
http://dx.doi.org/10.1038/s41419-020-03349-1

Ejemplares similares